Profarma’s Gross Revenue reached R$ 764.3 million in the 2Q09 and the Net Income increased 66.2% reaching R$ 17.9 million.

Rio de Janeiro, August, 03, 2009 – Profarma Distribuidora de Produtos Farmacêuticos S.A. (“Profarma” or “Company”) (Bovespa: PFRM3), one of the main distributors of the pharmaceutical industry in the country, discloses the result of the second quarter 2009 (2Q09). Profarma’s financial statements are prepared in accordance with the Brazilian Corporate Legislation, and in Real (R$), containing all the adjustments already regulated by CVM as well as the technical pronouncements of the Accounting Committee – CPC, aiming to adequate the company’s result with law n°11.638/07. The financial and operational information below, are presented on consolidated bases in accordance with the accounting practices adopted in Brazil. The result comparisons refer to the second quarter 2008 (2Q08) and the first quarter 2009 (1Q09).

Profarma’s non-financial information has not been revised by the external auditors.

HHIIGGHHLLIIGGHHTTSS FFOORR TTHHEE PPEERRIIOODD

Net Income increased 66.2% in relation to the

2Q08, reaching R$ 17.9 million, representing a Net Margin of 2.8%.

Growth of 60.0% in Ebitda, reaching R$ 37.8 million, well above the figures for the same period in 2008, with an Ebitda Margin of 5.8%.

A reduction of the Cash Cycle of the company in 9.2 days, reaching 58.7 days, the lowest level since the year 2006. This drop represented a Working Capital reduction of R$ 63.1 million.

For the fourth consecutive quarter the generation of operating Cash Flow has been positive reaching R$ 26.3 million, accumulating in 2009 a resource generation of R$ 62.9 million or 5.2% of the Net Operating Revenue.

Reduction of the Net Debt / Ebitda ratio of the company in 25.0% for the second quarter in a row, reaching 1.2x, leaving a position of 1.6x in the 1Q09.

Profarma disclosed to the market on May,22, 2009, a New Repurchase Program of its Shares stipulating the maximum number of 1,570,000 shares to be acquired.

TTEELLEECCOONNFFEERREENNCCEE

Portuguese Tuesday, August, 4th, 2009. 10:00 a.m. (Brazil) 09:00 a.m. (NY) Telephone: +55 (11) 2188-0188 Replay: +55 (11) 2188-0188 Code: PROFARMA English Tuesday, August, 4th, 2009 12:00 p.m. (Brazil) 11:00 a.m. (NY) Telephone: +1 (973) 935-8893 Code: 20269008 Replay: +1 (706) 645-9291 Code: 20269008

CCOONNTTAACCTTSS

Max Fischer CFO & IRO Beatriz Diez IR Coordinator Telephone: +55 (21) 4009-0276 Fax: +55 (21) 2491-3906 E-mail: ri@profarma.com.br

Disclosure of Results of the Second Quarter, 2009

About the Company: Profarma Distribuidora de Produtos Farmacêuticos S.A. has been active for 48 years in distributing pharmaceutical, personal care and cosmetic products in the most populous Brazilian states. With 12 distribution centers, being one of them exclusively for the hospital and vaccine segment, Profarma commercializes approximately 18.0 million units per month and serves 30,870 sales outlets, thus consolidating its position as one of the industry leaders in Brazil. Covering a geographic area that represents 91.0% of the consumer market for pharmaceutical products in Brazil, Profarma boasts a specialized and committed team that constantly strives to become the biggest and most profitable wholesale distributor of pharmaceutical products in the nation by means of consistent and sustainable results, keeping operating costs down, strengthening its competitive advantages and maximizing value for our stockholders.

SSUUMMMMAARRYY

Management Comments 03

Financial Highlights 04

Economic-Financial Performance

� Gross Revenue 05

� Gross Profit and Revenues from Services to Suppliers 06

� Operating Expenses 06

� Net Financial Expenses 07

� Net Income 07

� Ebitda 08

� Indebtedness 09

� Cash Flow 09 Operating Performance

� Service Level 11

� Logistics – Errors per Million (E.P.M.) 11

� Logistics – Productivity 11

� Sales per square meter of warehouse and Average sales per DC 12

� Sales Through Electronic Orders 12

� Capex 12

Capital Markets

� Share Performance 13

Relationship with Independent Auditor 14

Next Events 15

Attachment I – Statement of Income 16

Attachment II – Balance Sheet 17

Attachment III – Cash Flow 18

Attachment IV – Law nº. 11.638/07 and MP nº. 449/08: Understanding the impact on Profarma 19

MANAGEMENT COMMENTS

In the second quarter of 2009, the slowdown and the instability of the economy due to the world crisis which initiated by the end of the 3Q08, could still be seen, showing signs of rhythm reduction in some countries, such as Brazil and China. Aligned to the strategy traced and initiated in 2008, the company showed in this quarter expressive results regarding the search for the optimization of its financial resources. In this quarter, Profarma’s net income reached R$ 17.9 million, a result 66.2% above the one reached during the same period of the previous year when we reached R$ 10.8 million. The net margin of the company reached 2.8% in this quarter, having become the best mark reached by the company in similar quarters since 2006. The same way, our ebitda margin reached 5.8% in this quarter, 56.8% above the Ebitda margin which was released during the same period of the previous year, reaching R$ 37.8 million. It’s important to state that when comparing with all the same quarters (2Q06, 2Q07, 2Q08), since 2006 our best Ebitda margin had been of 4.0% in the 2Q06, even with a price increase similar to the one in 2009, in that time 5.5%. Reassuring and reinforcing Profarma’s objective of strengthening its financial solidity in this crisis scenario, the company generated for the fourth quarter in a row, a positive operating cash flow of R$ 26.3 million, accumulating in the first semester a cash generation of R$ 62.9 million. This result was directly related to the Company’s cash cycle reduction in this quarter of around 9 days, reaching its lowest level since December 2006. This way and for the second quarter in a row, the Company reduced its net debt / ebitda ratio in 25.0%, reaching 1.2x when it was of 1.6x in the 1Q09 and 1.9x in the 4Q08. Considering the macroeconomic scenario still unstable, our gross operating revenue in this 2Q09 increased 15.5% in relation to the previous quarter and 3.1% in relation to the 2Q08, reaching R$ 764.3 million. In this quarter, the positive results of the actions that started in 2008 were consolidated, and they were very important to face the most critical periods of the crisis and therefore, strengthen even more the Company´s position in the distribution sector. It’s important to highlight that in this quarter, Profarma’s shares went up 121.5% accumulating throughout the year 94.3%, a performance above Ibovespa’s valorization which was of 37.1% during the same period. Even taking into consideration this evolution, the actual value of its shares is still below its book value which was of R$ 13.88 on June, 30, 2009.

(R$ Millions) 2Q09 2Q08 % Variation 1Q09 % Variation

Financial Data

Gross Revenues 764.3 741.2 3.1% 661.8 15.5%

Branded 514.0 518.7 -0.9% 453.9 13.2%

Generic 41.2 42.4 -2.8% 29.5 39.6%

OTC 153.3 131.4 16.7% 129.3 18.5%

Health and beauty Products 27.0 29.2 -7.5% 23.2 16.4%

Hospitals and Vaccines 28.9 19.5 47.9% 25.8 11.8%

Net Revenues 646.5 642.8 0.6% 563.0 14.8%

Gross Profit 82.9 62.9 31.8% 57.8 43.4%

% Net Revenues 12.8% 9.8% 3.0 p.p 10.3% 2.5 p.p

Operating Expenses -49.6 -40.4 22.8% -42.2 17.6%

SGA Expenses -49.9 -51.1 -2.3% -45.9 8.7%

% Net Revenues -7.7% -8.0% 0.3 p.p -8.2% 0.5 p.p

Depreciation and Amortization -1.4 -1.1 24.7% -1.3 3.9%

% Net Revenues -0.2% -0.2% 0.0 p.p -0.2% 0.0 p.p

Rev. Services for Suppliers 3.7 10.5 -64.7% 5.3 -30.2%

% Net Revenues 0.6% 1.6% -1.0 p.p 0.9% -0.3 p.p

Other Oper. Rev. -2.0 1.3 - -0.3 762.4%

% Net Revenues -0.3% 0.2% -0.5 p.p 0.0% -0.3 p.p

Ebit 1 36.4 22.5 61.7% 15.8 130.3%

Ebit Margin (% Net Revenues) 5.6% 3.5% 2.1 p.p 2.8% 2.8 p.p

Ebitda 2 37.8 23.6 60.0% 17.1 120.7%

Ebitda Margin (% Net Revenues) 5.8% 3.7% 2.1 p.p 3.0% 2.8 p.p

Net Income 17.9 10.8 66.2% 6.7 166.0%

Net Margin (% Net Revenues) 2.8% 1.7% 1.1 p.p 1.2% 1.6 p.p

1 Ebit comprised of Ebitda minus depreciation.

2 Ebitda - Net income (loss) plus income tax and social contribution, net financial results, net non-operating results, other net operating revenues (expenses) non-recurring, depreciation, amortization.

FINANCIAL HIGHLIGHTS

ECONOMIC-FINANCIAL PERFORMANCE

Gross Revenue

In the 2Q09, Profarma’s gross revenue reached R$ 764.3 million, an increment of 3.1% in relation to the same period of the previous year, and 15.5% in relation to the 1Q09. It is also important to state that the growth was homogeneous all over the country for the fact that it was mainly due to Profarma’s focus given to independent customers in the beginning of the 4Q08.

In the analysis by geographical region, the best performance was the southeast with a 8.2% growth in comparison with the same period of the previous year.

In the analysis by category, the highlight in the 2Q09 was the hospital & vaccine segment, with a 47.9% growth in relation to the same period of the previous year. It is important to highlight the generic category performance, which showed an increase of 39.6% in relation to the previous quarter, a performance above the 18.0% growth of the generic national market during the same period.

Gross Revenues Evolution(R$ Million)

741.2

661.8

764.3

2Q08 1Q09 2Q09

Gross Revenues Evolution(R$ Million)

741.2

661.8

764.3

2Q08 1Q09 2Q09

Gross Revenues Breakdown

(R$ Million) 2Q09 2Q08 Chg. % 1Q09 Chg. %

Branded 514.0 518.7 -0.9% 453.9 13.2%

Generics 41.2 42.4 -2.8% 29.5 39.6%

OTC 153.3 131.4 16.7% 129.3 18.5%

Health and Beauty 27.0 29.2 -7.5% 23.2 16.4%

Hospitals + Vaccines 28.9 19.5 47.9% 25.8 11.8%

Total 764.3 741.2 3.1% 661.8 15.5%

Gross Revenues Breakdown

(R$ Million) 2Q09 2Q08 Chg. % 1Q09 Chg. %

Branded 514.0 518.7 -0.9% 453.9 13.2%

Generics 41.2 42.4 -2.8% 29.5 39.6%

OTC 153.3 131.4 16.7% 129.3 18.5%

Health and Beauty 27.0 29.2 -7.5% 23.2 16.4%

Hospitals + Vaccines 28.9 19.5 47.9% 25.8 11.8%

Total 764.3 741.2 3.1% 661.8 15.5%

Gross Profit and Revenues from Services to Suppliers

In the 2Q09, the consolidated gross profit reached R$ 82.9 million, which represented a gross margin of 12.8%, 3.0 percentage points above the gross margin in the 2Q08, when we reached a gross profit of R$ 62.9 million and 2.5 percentage points above the gross margin achieved in the previous quarter.

For a better understanding of the effective gross margin behavior it is important to add to the gross profit the revenues from services to suppliers, due to the relevance of this service modality in the sales mix of the company.

In the 2Q09, the revenues from services to suppliers reduced 1.1 percentage point when comparing to the same period of the previous year and 0.4 percentage point in relation to the previous quarter, mainly due to the increase of the share of this revenues reimbursed through additional commercial discounts.

This way, by adding to the gross profit the revenues from services to suppliers, the gross margin of the 2Q09 reached 13.4%, 2.0 percentage points bigger when compared to the gross margin of the 2Q08 and 2.2 percentage points with relation to the gross margin verified in the 1Q09. The increase of the gross margin seen in the 2Q09 in relation to the previous quarter, was mainly due to the price increase impact which occurred on March, 31, 2009 estimated in 2.0 percentage points or R$ 12.9 million and also due to the continuity of a more conservative competitive scenario in the market.

Operating Expenses

In the 2Q09, the operating expenses, represented by administrative, commercial, and logistic expenses, (excluding the depreciation, revenues from services to suppliers, and other revenues) reached R$ 49.9 million or 7.7% of the net revenue, 0.3 percentage point below the same period of the previous year and 0.5 percentage point lower when compared to the previous quarter.

It’s important to state that in this total amount it’s included an INSS additional provision totaling R$ 3.1 million referred to a law suit regarding the labor accident insurance constitutionality. Such provisions are referred to the years 1999 and 2000, therefore they aren’t recurring.

(R$ Million and as % Net Revenues)

Gross Profit and Revenues from Services to Suppliers

62.9 57.8

82.9

3.7

10.5

5.3

11.4% 11.2%

13.4%

2Q08 1Q09 2Q09

Gross Profit Revenues from Services to Suppliers Adjusted GP Margin (%)

(R$ Million and as % Net Revenues)

Gross Profit and Revenues from Services to Suppliers

62.9 57.8

82.9

3.7

10.5

5.3

11.4% 11.2%

13.4%

2Q08 1Q09 2Q09

Gross Profit Revenues from Services to Suppliers Adjusted GP Margin (%)

This way, in the operating expenses analysis, excluding this provision, we would have a real reduction of around 9.5% in relation to the same period of the previous year, reaching 7.2% of the net operating revenues or R$ 46.8 million, mainly due to the commercial expenses reduction, 0.7 percentage point or R$ 4.5 million. This drop was mainly due to the advertisement expenses reduction, regarding prizes conceded to certain customers who achieved the minimum sales volume which had been agreed before.

In the same way, when we compare the total operating expenses in the 2Q09 with the previous quarter, we can observe a real drop even bigger of 11.7% or 1.0 percentage point. This drop was mainly due to a reduction of 0.7 percentage point in the commercial expenses and 0.3 percentage point in the logistic expenses.

Regarding the commercial expenses reduction, not only the reduction with advertisement expenses of R$ 2.3 million contributed but also the sales growth during the period which was of 15.5% in relation to the previous quarter.

Regarding the logistic expenses, we can observe a small value increase (R$ 0.6 million) which allied to the sales growth of 15.5% during the period, represented a scale gain of 0.3 percentage point.

In the analysis of other operating revenues/ (expenses), we can observe in the 2Q09 an expense of R$ 2.0 million in comparison with a revenue of R$ 1.3 million during the same period of the previous year, mainly due to the reduction of the total grant amount obtained with the industries for the implementation of promotional campaigns. When comparing with the previous quarter, we had an expense increase of R$ 1.8 million, mainly due to a bigger concentration of the expenses related to promotional campaigns in this period (R$ 0.6 million).

Net Financial Expenses

The net financial expenses reached R$ 8.5 million in the 2Q09, representing a reduction of R$ 0.2 million in relation to the same period of the previous year. It is important to state that in the net financial expenses of this quarter, an additional interest provision of R$ 2.5 million is included, referred to the law suit regarding the INSS labor accident insurance constitutionality. Such provisions are referred to the years 1999 and 2000, therefore they aren’t recurring. This way, in the net financial expenses analysis, excluding such provision, we would have a reduction of R$ 2.7 million, mainly related to a reduction of 30.0% in the Company’s debt level.

In this same basis, when comparing the net financial expenses of this quarter with the 1Q09, we can observe a reduction of R$ 1.8 million mainly due to the reduction of the net financial adjustments to present value adjustments (AVP) of R$ 1.6 million referred to law n° 11.638/07.

Net Income

In the 2Q09 the consolidated net profit reached R$ 17.9 million or 2.8% of the net operating revenue, representing an increment of 66.2% in relation to the same period of the previous year (R$ 10.8 million with 1.7% of net margin) and 167.2% in relation to the previous quarter (R$ 6.7 million, with 1.2% of net margin), becoming this quarter the best mark reached by the company in similar quarters since 2006.

This result was mainly due to the increase of the Company’s operating margin in the period, reaching 5.2% of the net operating revenue, representing an increment of 1.7 percentage point in relation to the same period of the previous year, and 2.4 percentage points in relation to the previous quarter.

It is important to state that excluding from this result the non recurring additional provision of INSS as described previously, the net profit of the Company would achieve R$ 21.6 million, or 3.3% of the net operating revenue, representing a growth of 100.0% and 222.4% in relation to the 2Q08 and to the 1Q09, respectively.

Ebitda

In the 2Q09 the company reached an Ebitda of R$37.8 million, representing an Ebitda margin of 5.8%, being this the biggest margin achieved by the Company in comparable quarters (2Qs) in the past four years, even taking into consideration the 2Q06, when the price increase was similar to the 2Q09, but the Ebitda margin was of 4.0%.

When comparing with the same quarter of the previous year, the increment was of R$ 14.2 million or 2.1 percentage points, mainly due to the Company’s operating margin increase of 1.7 percentage point. This way, when comparing with the previous quarter we can observe an increase of R$ 20.7 million or 2.8 percentage points, also related mainly to the operating margin increment of the company in R$ 17.7 million or 2.4 percentage points.

Net Income(R$ Million and as % Net Revenues)

10.8

6.7

17.9

2.8%

1.2%1.7%

2Q08 1Q09 2Q09

Net Income(R$ Million and as % Net Revenues)

10.8

6.7

17.9

2.8%

1.2%1.7%

2Q08 1Q09 2Q09

(R$ Million) 2Q09 2Q08 % Variation 1Q09 % Variation

Net Income 17.9 10.8 66.2% 6.7 166.0%Non Recurring Expenses 3.1 0.0 - 0.2 -IR / CS 6.9 3.0 128.5% 1.1 529.6%Financial Expenses 8.5 8.7 -2.6% 7.8 9.0%Depreciation and Amortization 1.4 1.1 24.7% 1.3 3.9%Ebitda 37.8 23.6 60.0% 17.1 120.7%Ebitda Margin 5.8% 3.7% 59.1% 3.0% 92.2%

(R$ Million) 2Q09 2Q08 % Variation 1Q09 % Variation

Net Income 17.9 10.8 66.2% 6.7 166.0%Non Recurring Expenses 3.1 0.0 - 0.2 -IR / CS 6.9 3.0 128.5% 1.1 529.6%Financial Expenses 8.5 8.7 -2.6% 7.8 9.0%Depreciation and Amortization 1.4 1.1 24.7% 1.3 3.9%Ebitda 37.8 23.6 60.0% 17.1 120.7%Ebitda Margin 5.8% 3.7% 59.1% 3.0% 92.2%

Indebtedness

The net debt position in the end of the 2Q09 reached R$ 110.8 million, representing a reduction of R$ 9.9 million in relation to R$ 120.7 million of March, 2009, mainly due to the positive cash flow generated in the operating activities of R$ 26.3 million which occurred in this period. This way, the net debt / ebitda ratio of the Company was reduced for the second consecutive quarter, in 25.0% reaching 1.2x at the end of the 2Q09.

It is important to state that during the 2Q09, Profarma paid of R$ 46.4 million of short term loans, which carried the impact of the high spreads and interest rates throughout the 4Q08. This way, the total of the Company’s remaining debt, R$ 145.4 million won’t be affected by the high spreads verified as of the 4Q08, and so returning to the spreads which were negotiated during the extending of Profarma’s debt profile in the 4Q07, around 10% above the CDI.

Cash Flow

Ebitda e Ebitda Margin(R$ Million and as % Net Revenues)

23.6

17.1

37.8

5.8%

3.0%3.7%

2Q08 1Q09 2Q09

Ebitda e Ebitda Margin(R$ Million and as % Net Revenues)

23.6

17.1

37.8

5.8%

3.0%3.7%

2Q08 1Q09 2Q09

(R$ Million) 2Q09 2Q08 % Variation 1Q09 % Variation

Cash Flow Generated / (Used) in Operating Activities 26.3 (24.0) - 36.6 -

Internal Cash Generation 24.8 16.7 48.4% 11.4 117.5%

Operating Assets Variation 1.5 (16.2) - 25.2 -

Trade Accounts Receivable (33.2) (11.6) -187.1% 51.5 -164.4%

Inventories 11.5 (0.3) - 8.3 -

Suppliers 18.4 (4.2) - (25.3) -

Other Items 4.8 (0.1) - (9.4) -

Cash Flow (Used) in Investing Activities (2.7) (3.1) 13.8% (3.3) 20.1%

Cash Flow Generated / (Used) by Financing Activities (61.1) 38.5 - (6.2) -

Net Increase / (Decrease) in Cash (37.4) 11.5 - 27.1 -

(R$ Million) 2Q09 2Q08 % Variation 1Q09 % Variation

Cash Flow Generated / (Used) in Operating Activities 26.3 (24.0) - 36.6 -

Internal Cash Generation 24.8 16.7 48.4% 11.4 117.5%

Operating Assets Variation 1.5 (16.2) - 25.2 -

Trade Accounts Receivable (33.2) (11.6) -187.1% 51.5 -164.4%

Inventories 11.5 (0.3) - 8.3 -

Suppliers 18.4 (4.2) - (25.3) -

Other Items 4.8 (0.1) - (9.4) -

Cash Flow (Used) in Investing Activities (2.7) (3.1) 13.8% (3.3) 20.1%

Cash Flow Generated / (Used) by Financing Activities (61.1) 38.5 - (6.2) -

Net Increase / (Decrease) in Cash (37.4) 11.5 - 27.1 -

Profarma’s cash and cash equivalents in the 2Q09 showed a R$ 37.4 million reduction, mainly due to the R$ 61.1 million used in the financing activities, R$ 2.7 million used in the investment activities, compensated by the cash generation in the operating activities of R$ 26.3 million.

In the 2Q09, the Company reached its lowest cash cycle, 58.7 days, since December 2006. Such expressive drop of 9.2 days, resulted in a working capital reduction of around R$ 63.1 million. Some factors contributed to this reduction, such as the drop for the sixth consecutive quarter of the Company’s sales average terms (1.9 days), and also the expressive 7.5 day reduction in our inventory level, reaching 46.5 days at the end of the 2Q09.

The cash flow generated in the operating activities of R$ 26.3 million was mainly due to the internal cash generation of R$ 24.8 million and the positive variation in the operating assets of R$ 1.5 million.

The internal cash generation in the 2Q09 of R$ 24.8 million was 117.5% bigger in relation to the previous quarter, mainly due to the increase of the net profit in the period of R$ 11.2 million.

The positive variation of the operating assets of R$ 1.5 million, was mainly due to a net reduction in the inventories, R$ 11.5 million, an increase in the suppliers’ balance of R$ 18.4 million, and a reduction of the tax recoverable balance of R$ 5.1 million. Such resources were partially consumed by the increase in the receivables balance of R$ 33.2 million.

In the 2Q09 the R$ 61.1 million used in the financing activities were mainly due to the net reduction of R$ 46.4 million in the debt position during this period and also due to the resources invested in the shares repurchase plans of the Company, R$ 10.6 million.

In this second quarter of the year, the R$ 2.7 million used in the investing activities were mainly directed to machines and equipment, totaling R$ 1.4 million.

3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08

Cash Cycle - Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 61.8 65.8

Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 47.0 45.9

Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 42.5 49.9

Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 27.7 29.9

* Average

(1) Average of Gross Revenues in the Quarter(2) Average of COGS in the Quarter(3) Average of COGS in the Quarter

1Q09

67.9

42.4

54.0

28.5

2Q09

58.7

40.5

46.5

28.4

3Q06 4Q06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08

Cash Cycle - Days * 49.3 53.4 62.5 69.6 67.8 64.3 68.8 67.2 61.8 65.8

Accounts Receivable (1) 45.2 50.0 54.6 53.1 50.9 51.7 50.7 49.2 47.0 45.9

Inventories (2) 33.1 44.7 43.4 47.2 41.3 48.6 47.9 45.7 42.5 49.9

Accounts Payable (3) 29.0 41.3 35.6 30.7 24.5 36.0 29.8 27.7 27.7 29.9

* Average

(1) Average of Gross Revenues in the Quarter(2) Average of COGS in the Quarter(3) Average of COGS in the Quarter

1Q09

67.9

42.4

54.0

28.5

2Q09

58.7

40.5

46.5

28.4

OPERATING PERFORMANCE

Service Level

This indicator checks the percentage of units shipped out in relation to the units ordered by our customers and it is one of the key factors for our customers when selecting a distributor.

The service level in the 2Q09 was of 92.0%, a drop of 0.8 percentage point in relation to the same period of the previous year and an improvement of 1.3 percentage point in relation to the previous quarter. Such variations are considered in expected levels and also acceptable by the Company.

Logistics – Errors per Million (E.P.M.)

This indicator measures the numbers of errors made by millions of delivered units. It is of great relevance for our customers since it lowers the quantity of re-work needed to meet the order, but also in terms of the sales loss risk for the product not being correctly delivered.

When comparing the 2Q09 with the 2Q08, this indicator showed an increase in the quantity of errors per million of 14.3%, reaching 112.0 E.P.M. in this quarter in face of 98.0 of the 2Q08, mainly related to the production adjustments to a higher number of orders taken due to the increase of the medium and small customer’s participation in the Company’s sales mix. When we compare the 2Q09 with the previous quarter we can observe an increase of 17.9%, mainly due to the recurring change in the sales profile in one of our branches, increasing the number of production short break cuts, whose impacts have already been minimized throughout July.

Logistics – Productivity

This indicator measures the total of units delivered per man/hour worked in the logistic area, (inventory and shipment) in such a way we can follow up and control its variation reflexes in the total area expenses, being of great relevance in order to search the best and lowest cost for the company.

The productivity level in the 2Q09 was 79,1, a result 2.3% lower than the one registered in the 2Q08, mainly due to the changes in the Company’s sales profile. When comparing with the previous quarter, there was an increase of 10.2%, reaching 79,1 in face of 71,8, mainly related to the sales growth of 15.5% shown in this quarter.

(R$ Million) 2Q09 2Q08 % Variation 1Q09 % Variation

Indicators

Service Level 92.0% 92.8% -0.8 p.p. 90.7% 1.3 p.p.

Logistics - E.P.M. 1 112.0 98.0 14.3% 95.0 17.9%

Logistics - Productivity 79.1 81.0 -2.3% 71.8 10.2%

Sales per m2 of Distribution Center 14.7 15.5 -5.2% 12.7 15.5%

Average Sales per Distribution Center 63.7 67.5 -5.6% 55.1 15.5%

Sale through eletronic orders 59.6% 58.9% 0.7p.p. 56.1% 3.5 p.p.

1 - Errors per million

Sales per square meter of warehouse and Average sales per DC

These indicators measure the efficiency and productivity of our distribution centers, having as main objective the continuous search for low costs structure for the company.

When comparing the 2Q09 with the same period of the previous year, the sales per square meter indicator, showed a reduction of 5.2%, mainly due to the increase of the installed capacity, represented by several actions throughout this period: opening of the exclusive Distribution Center for hospitals and vaccines (June 2008), expansion of the Minas Gerais DC (December 2008), moving of the Bahia DC (February, 2009), and the expansion of the São Paulo DC (March 2009). When comparing the 2Q09 with the 1Q09, this indicator showed an increase of 15.5%, principally related to the sales growth of 15.5% shown in this quarter.

The average sales per distribution center indicator, showed a decrease of 5.6% in comparison with the same period of the previous year, mainly due to the opening of the DC exclusively for the hospital and vaccine segment which occurred in June, 2008. Regarding the previous period we observed an increase of 15.5%, aligned with the Company sales growth during the same period.

Sales Through Electronic Orders

This indicator measures the sales quota received by electronic orders and aims to improve the quality, and speed up the order capture process as well as reduce the expenses with telemarketing, for the fact that the timing with electronic orders is 50% below the one performed by an operator.

This service enables the customer, among other advantages, receive a prompt return of the quantity attended and a copy of the invoice so that the receiving process of the product be faster and no errors.

The sales volume through electronic order is still evolving, reaching in the 2Q09 59.6% of the total sales, which represents an increase of 0.7 percentage point, and 3.5 percentage points in comparison with the 2Q08 and 1Q09, respectively. We shall mention that even having increased the small and medium customer’s participation in the Company’s sales – such reason was responsible for the indicator drop in the previous quarter – the Company has as objective to increase the sales through the electronic order, and has already achieved its figures which were shown before these changes in the sales profile.

Capex

In the 2Q09 all investments totaled R$ 2.8 million representing an R$ 0.3 million reduction in relation to the same period of the previous year and an R$ 0.7 reduction in relation to the previous quarter. Such variation occurred mainly due to the R$ 0.2 million reduction of IT investments when comparing with the same period of the previous year. When comparing to the previous quarter the main reduction R$ 0.9 million was related to machines and equipment.

CAPITAL MARKETS

Share Performance

Profarma’s shares ended the 2Q09 at R$ 10.30 which represents an increase of 121.5% in relation to value reached in March, 2009, R$ 4.65. It’s important to mention that at the end of July (07/31/2009), the shares showed a valorization of 31,1%, accumulating through the year a 154,7% performance, above Ibovespa during the same period, which was of 45,8%. Even with this valorization, the Company’s share value, just like many other companies in Brazil, is found below its book value, which was of R$ 13.88 on June, 30th, 2009.

In 2008, the subprime crisis deepening, provoked an unprecedented financial deleveraging process, allied to the credit shortening. The impact could be seen in a larger proportion in the small caps companies, due to the expressive liquidity reduction provoked by the risk aversion increase in the financial markets. A very common flow in this period was the migration of the investors focused in mid and small caps companies to the large caps, which in turmoil moments are considered more defensive considering mainly the liquidity. In 2009, Bovespa´s growth resumption and the return of investors to Companies with lower liquidity, promoted in an expressive way, Profarma’s liquidity, as shown in the table below.

Daily Average - Shares and Number of Trades

Source: Economática - The daily average metric used in the graph is the average of the last thirty trading sessions before each day for the number of shares and for the number of trades, according to the Bovespa standard.

Return to Mid

and small Caps

Ações

Negócios0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

2-jan-08 2-may-08 2-sep-08 2-jan-09 2-may-090

10

20

30

40

50

60

70

Liquidity Reduction

Mid, Small Large

numbersofshares

numberoftrades

Daily Average - Shares and Number of Trades

Source: Economática - The daily average metric used in the graph is the average of the last thirty trading sessions before each day for the number of shares and for the number of trades, according to the Bovespa standard.

Return to Mid

and small Caps

Ações

Negócios0

20,000

40,000

60,000

80,000

100,000

120,000

140,000

160,000

180,000

2-jan-08 2-may-08 2-sep-08 2-jan-09 2-may-090

10

20

30

40

50

60

70

Liquidity Reduction

Mid, Small Large

Liquidity Reduction

Mid, Small LargeMid, Small Large

numbersofshares

numberoftrades

Ibovespa (1) IGC (1)

Share Price

03/31/2009

Share Price

06/30/09

Note (1): Comparative evolution in Index base points

Profarma Shares - Comparative Performance (PFRM3)

Var. (%)

R$ 4.65 40.925 3.878

51.465 4.944

25.8% 27.5%121.5%

R$ 10.30

Profarma vs Ibovespa

137

194

15

35

55

75

95

115

135

155

175

195

29-Dec-08 30-Jan-09 28-Feb-09 31-Mar-09 30-Apr-09 29-May-09 30-Jun-09

Ibovespa Profarma

Profarma vs Ibovespa

137

194

15

35

55

75

95

115

135

155

175

195

29-Dec-08 30-Jan-09 28-Feb-09 31-Mar-09 30-Apr-09 29-May-09 30-Jun-09

137

194

15

35

55

75

95

115

135

155

175

195

29-Dec-08 30-Jan-09 28-Feb-09 31-Mar-09 30-Apr-09 29-May-09 30-Jun-09

Ibovespa Profarma

Profarma disclosed to the market on May 22nd, 2009, a new share repurchase program stipulating the maximum number of 1,570,000 shares to be acquired. On June 30th, 2009, Profarma had already acquired 417,100 shares, representing 26.6% of the total plan. The objective of the Company in this operation is to search for maximize value generation for the shareholders, having seen its share value in Bovespa.

RELATIONSHIP WITH INDEPENDENT AUDITOR

Following the Instruction CVM nº. 381, of January 14th, 2003, regarding the need of disclosure by the audited Entities of the information about services by the independent auditor other than external audit, Profarma states that the Company policies regarding hiring its independent auditors for services not related to external audit aims at assuring that there are no interests conflicts, loss of independence or objectivity and are based on the principles that preserve the auditor’s independence.

The work of special review of the quarter ended on June 30st, 2009 has been accomplished by KPMG, which has not rendered auditing services non related to auditing during this period.

NEXT EVENTS

• Conference Call – Results of the 2st Quarter, 2009

Date: Tuesday, August 4th, 2009.

In Portuguese 10h00 a.m. (Brasília time) Telephone: (11) 2188-0188 Replay: (11) 2188-0188

Code: PROFARMA

In English 12:00 p.m. (Brasília time) Telephone: +1 (973) 935-8893

Code: 20269008 Replay: +1 (706) 645-9291 Code: 20269008

Live transmission over the internet: http://www.profarma.com.br/ir

Attachment I – Statement of Income* (R$ thousands)

For Quarters ended Jun 30 and Mar 31:(Thousands of Reais, except share data)

2Q09 % 2Q08 % 1Q09 %Gross Operating Revenue: From Sales of Products 764,309 741,200 661,750

764,309 118.2% 741,200 115.3% 661,750 117.5%Deductions from Gross Operating Revenue: Taxes and Other Deductions (117,789) (98,430) (98,781)

Net Operating Revenue 646,520 100.0% 642,770 100.0% 562,969 100.0%

Cos t of Goods Sold and Services Rendered (563,591) (579,850) (505,141)

Gross Profit 82,929 12.8% 62,920 9.8% 57,828 10.3%Operating Revenue (Expenses) General and Adm inis trative (16,408) (13,127) (11,151) Selling and Marketing (14,953) (19,453) (16,817) Logis tics and Dis tribution (18,573) (18,541) (17,967) Depreciation and Amortization (1,351) (1,083) (1,300) Revenue from Services Rendered to Suppliers 3,712 10,519 5,320 Other Operating Revenue (Expenses ) (2,028) 1,306 (266)

(49,601) -7.7% (40,379) -6.3% (42,181) -7.5%

Operating Results prior to Financial Results 33,328 5.2% 22,541 3.5% 15,647 2.8%

Other Revenues / (Expenses) 5 0.0% - 0.0% - 0.0%5 0.0% - 0.0% - 0.0%

Financial Results Financial Revenues 813 40 818 Financial Revenues AVP 699 1,644 339

Financial Expenses Banks (5,208) (8,841) (5,491) Financial Expenses AVP (1,799) (1,266) (2,989) Other Financial Expenses (3,025) (321) (492)

(8,515) -1.3% (8,744) -1.4% (7,815) -1.4%

Operating Income (Loss) 24,813 3.8% 13,797 2.1% 7,832 1.4%

Income (Loss) before Taxation 24,813 3.8% 13,797 2.1% 7,832 1.4%

Taxation Provis ion for Corporate Incom e Tax (5,105) (2,182) (1,034) Provis ion for Social Contribution (1,938) (832) (399) Provis ion for Deferred Income Tax 155 - 339

(6,888) -1.1% (3,014) -0.5% (1,094) -0.2%

Net Income for the Quarter 17,925 2.8% 10,783 1.7% 6,738 1.2%

Net per Batch of One Thousand Shares (in Reais) 518 297 186

Number of Shares at End of Quarter 34,600,000 36,300,000 36,300,000

Consolidated

* According to the new Law nº. 11.638/07

Attachment II – Balance Sheet* (R$ thousands)

As of Jun 30 and Mar 31(Thousands of Reais)

A s s e t s Liabilities and Equity30/06/09 30/06/08 31/03/09 30/06/09 30/06/08 31/03/09

Current Assets: Current Liabilities: Cash and cash equivalents 34,586 44,627 71,978 Suppliers 177,762 177,203 159,812 Trade Accounts Receivable 344,122 404,793 312,110 Loans and Financings 28,285 63,298 79,205 Inventories 291,353 294,449 302,834 Salaries and Payroll Taxes 6,741 6,399 5,830 Taxes Recoverable 138,885 114,716 143,953 Accrued Taxes and Fees 20,920 21,957 20,656 Advances 1,708 1,199 1,171 Dividends and Interes t on Capital Inves ted - - 4,061 Other Accounts Receivable 4,021 4,880 5,251 Other Accounts Payable 911 613 910

814,675 864,664 837,297 234,619 269,470 270,474

Noncurrent Assets Noncurrent Liabilities Long-Term Assets Long-Term Liabilities:

Accrued Taxes and Fees 18,194 15,323 14,008 Loans and Financings 117,122 144,608 113,520 Provis ion for Contingencies 8,057 8,416 8,536

Depos its in Court 403 358 403 Other Accounts Payable 650 - - Deferred Income Taxes 4,216 4,545 4,061 Deferred Income Other Accounts Receivable 8,414 7,362 7,553 Tax Incentives - - -

13,033 12,265 12,017 144,023 168,347 136,064

Permanent Assets: Stockholders' Equity: Capital Stock 393,578 393,578 393,578 Treasury Stock (4,025) - (6,441)

Tangible Fixed Assets 23,663 17,775 22,337 Capital Reserve 41,648 34,124 41,344 Intangible Fixed Assets 7,658 7,274 7,690 Revenue Reserve 24,523 28,052 37,584 Deffered - - - Retained Earnings 24,663 8,407 6,738

31,321 25,049 30,027 480,387 464,161 472,803

Total Assets 859,029 901,978 879,341 Total Liabilities and Equity 859,029 901,978 879,341

ConsolidatedConsolidated

* According to the new Law nº. 11.638/07

Attachment III – Cash Flow Statement* (R$ thousands)

Quarters Ended Jun 30 and Mar 31:(Thousands of Reais)

2Q09 2Q08 1Q09 Operating Activities

Net Income for Quarter 17,925 10,783 6,738 Net Income 17,925 10,783 6,738

Reconciliation of Net Income to Net CashDepreciation and Amortization 1,351 1,083 1,280 Adjustments Law 11.638/07 (90) (86) (1,164) Provion for Contingencies 44 70 79 Accrued Interest on Loans (938) 4,120 4,054 Deferred Income Taxes (155) - (339) INSS Additional Provision 5,594 - - Other 1,083 754 760

24,814 16,724 11,408 (Increase) Decrease in Operating Assets

Trade Note Receivable (33,187) (11,559) 51,522 Inventories 11,480 (285) 8,326 Taxes Recoverable 5,068 (17,241) 3,480 Other Sundry Items (168) 645 1,148

(16,807) (28,440) 64,476 Increase (Decrease) in Operating Liabilities

Suppliers (Trade Accounts Payable) 18,422 (4,211) (25,265) Salaries and Payroll Taxes 911 1,021 513 Taxes Recoverable (1,144) (8,918) (14,386) Other Sundry Items 148 (136) (149)

18,337 (12,244) (39,287)

Cash Used in Operating Activities 26,344 (23,960) 36,597

Investing ActivitiesAdditions to Fixed / Deferred Assets (2,765) (3,092) (3,368) Write of Fixed Assets 101 - 34

Cash (Used in) / Generated Provided by Investing Activities (2,664) (3,092) (3,334)

Financing ActivitiesDividends Paid (4,061) (7,279) - Treasury stock (10,646) - (1,675) Loans and Financings (46,365) 45,812 (4,524)

Cash (Used in) / Provided by Financing Activities (61,072) 38,533 (6,199)

Increase / (Decrease) in Cash (37,392) 11,481 27,064

Cash and Cash Equivalents at End of Quarter 34,586 44,627 71,978 Cash and Cash Equivalents at Beginning of Quarter 71,978 33,146 44,914

(37,392) 11,481 27,064

Consolidated

Cash and Cash Equivalents in Quarter

* According to the new Law nº. 11.638/07

Attachment IV – Law nº. 11.638/07 and MP nº. 449/08: Understanding the impact on Profarma

In the 2008 financial statements of Profarma, the company adopted for the first time the alterations in the Brazilian Corporate Legislations introduced by the law nº. 11.638 of December 2007, with the changes introduced by the provisional measure nº. 449, of 03/12/2008.

Not only the law nº.11.638/07 but also the MP nº. 449 changed the law nº. 6404/76 relatively to the elaboration and disclosure of the financial statements.

The changes introduced were standardized by technical pronouncements of the Accounting Pronouncement Committee (CPC’s) and fully adopted by the Brazilian Securities Commission (CVM). Such pronouncements sought to give a definite understanding of how these changes would be applied in accounting.

As provided by law nº. 11.638/07, the company opted to adopt as the transition date, 01 of January, 2007. This way all the adjustments with impacts in income statement prior to this year were directly accounted in shareholders equity, according to the technical pronouncement CPC nº. 13.

It is important to state that the adjustments referred to years before 2007, which were directly accounted in shareholders equity, don’t have retroactive effects over the financial statements of those years.

On the other hand, the adjustments related to the changes introduced for the years 2007 and 2008 are already incorporated in the figures published, producing all the effects, respecting all the definitions issued by the technical pronouncements (CPCs).

In the end of 2008, the Accounting Pronouncement Committee had already issued 15CPCs, which in a certain way resume the main changes introduced by the new law nº. 11.638/07 and by the MP nº. 449/08.

Regarding Profarma, adjustments had to be made for 7 CPCs, and down under we describe the most important ones, for a better understanding of the changes which occurred in 2007 and 2008 regarding the income statements of 2007 and 2008, that will be reflected in the financial statements of subsequent years.

- Governmental Grants (CPC nº. 07):

VAT Fiscal Benefit According to the CPC no. 07, which concerns grants and governmental subsidies, the VAT Tax benefit that wasn’t previously recognized in the income statement (being booked directly to shareholders’ equity), starts to be recognized in it, as of the initial adopted date of the new law, 01/01/2007, in Profarma’s case.

According to CPC no 07, this change is not applicable in the year 2006, due to the initial date adopted by the company, 01/01/2007.

With regard to the treatment related to income taxes and to dividends basis the CPC no. 07 defines that the procedures held before will continue valid, in other words, this VAT Tax benefit is not taxable regarding income taxes and will not be included in the dividends basis.

- Adjusts to Present Value (CPC nº. 12):

According to the new law no. 11638/07 and following the technical pronouncement CPC nº. 12, certain accounts receivable (customers) and payable (suppliers) of long-term will be adjusted to its present value based on specific interest rates.

For Profarma the adjustments of present value of the long term accounts receivable are calculated for trade notes with terms higher than the sales average term of each quarter, using as interest rate the average cost of Profarma’s debt at the end of same period.

Likewise, the present value adjustments of the long term accounts payable are calculated for trade notes with terms higher than the purchase average term of each quarter, using as the interest rate, the average cost of Profarma’s debt at the end of the same period.

The effects of such adjustments are reflected in Profarma’s income statements this way:

• Accounts Receivable (customers): the contra entry of adjustments to present value of accounts receivable is in the gross revenue (reduction of gross revenues). The adjustments in the accounts receivable are treated as financial income and will be appropriated to the result (in the account financial revenue / AVP) as the notes are being paid off.

• Accounts payable (suppliers): the contra entry of adjustments to present value of accounts payable is part in the cost of goods sold (reduction of CGS) and part in inventory (reduction of inventory). The adjustments of accounts payable are considered as financial expenses and will be appropriated to the result (in the account financial expenses / AVP) as these notes are being paid off.

- Compensation Plan based on Sttocks (CPC nº. 14):

The benefit granted to administrators and employees related to compensation plans based on stocks, will be recorded as operating expense. When calculating the fair value of the benefit, the Black & Scholes binomial method was used, with the effects being appropriated according to the maturity date of each vesting period of the plan.

- Other CPCs – nº. 04, nº. 06, nº. 10 and nº. 13:

Regarding the other CPCs applicable to Profarma (nº. 4 – Intangible Assets, nº. 06 – Commercial Leasing and nº. 10 – Financial Instruments and nº. 13 – Initial Adoption of Law nº. 11638/07), the impacts in the years of 2008 and 2009 were smaller when compared to the others and their effects can be found in Notes.

About the Company: Profarma Distribuidora de Produtos Farmacêuticos S.A. has been active for 48 years in distributing pharmaceutical, personal care and cosmetic products in the most populous Brazilian states. With 12 distribution centers, being one of them exclusively for the hospital and vaccine segment, Profarma commercializes approximately 18.0 million units per month and serves 30,870 sales outlets, thus consolidating its position as one of the industry leaders in Brazil. Covering a geographic area that represents 91.0% of the consumer market for pharmaceutical products in Brazil, Profarma boasts a specialized and committed team that constantly strives to become the biggest and most profitable wholesale distributor of pharmaceutical products in the nation by means of consistent and sustainable results, keeping operating costs down, strengthening its competitive advantages and maximizing value for our stockholders.

We make statements about future events that are subject to risks and uncertainties. Such statements are based on the beliefs and suppositions of

our Management and information to which the Company currently has access. Statements about future events include information regarding our

present intentions, beliefs or expectations, as well as those of the members of the Company’s Board of Directors and Executive Officers Committee.

The qualifications in relation to statements and information about the future also include information regarding potential or presumed operating

results, as well as statements that are preceded or followed by or include the words "believe", "may", "will", "continue", "expect", "forecast",

"intend", "plan", "estimate" or similar expressions. The statements and information regarding the future are not guarantees of performance. The

involve risks, uncertainties and suppositions because they refer to future events, thus depending on circumstances that may or may not occur.

Future results and creation of value for stockholders may differ to a material degree from those expressed or suggested by statements in relation to

the future. Many of the factors that determine such results and amounts are beyond Profarma’s ability to control or predict matters.